Peginterferon alfa-2a for AIDS-associated Kaposi sarcoma: experience with 10 patients.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 23912848.
- Also identified by DOI 10.1093/cid/cit517.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In this observational cohort study, 10 patients with extensive or treatment-refractory AIDS-associated Kaposi sarcoma were treated with peginterferon alfa-2a. Tumor responses were observed in 9 patients with a median progression-free survival of 645 days. Peginterferon alfa-2a could be an effective therapy for extensive or treatment-resistant Kaposi sarcoma.
Medical subject headings
- AIDS-Related Opportunistic Infections
- Interferon-alpha
- Polyethylene Glycols
- Sarcoma, Kaposi